TRAIL Rabbit anti-Human, Rat, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA1955
PA1-955 detects TNF-related apoptosis inducing ligand (TRAIL) from human and rat tissues and cells. PA1-955 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~32 kDa protein representing TRAIL from HEK293 cell lysate. PA1-955 immunizing peptide corresponds to amino acid residues 207-220 from human TRAIL. PA1-955 immunizing peptide (Cat. No. PEP-046) is available for use in neutralization and control experiments.Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas. Another member in the TNF family has been identified and designated TRAIL (for TNF-related apoptosis inducing ligand) and Apo-2L (for Apo-2 ligand). Receptors for TRAIL include two death domain containing receptors, death receptor 4 (DR4) and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. TRAIL is a type II membrane protein and expressed in a variety of human tissues. Like TNF and Fas ligand, TRAIL induces apoptosis and NF-kB activation in many tissues and cells.
|Synthetic Peptide: C V(207) Q Y I Y K Y T S Y P D P I(230)|
|Antigen affinity chromatography|
|PBS with 1mg/mL BSA and 0.05% sodium azide|
|Apo2L, Apo-2 Ligand, TNF-Related Apoptosis-Inducing Ligand, Tumor necrosis factor ligand, superfamily member 10, TRAIL protein, CD253 antigen, TNFSF10|
|-20° C, Avoid Freeze/Thaw Cycles|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok